[{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Urovant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Urovant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Sumitovant Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Phase III","graph3":"Sumitovant Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitovant Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sumitovant Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Solifenacin Succinate","moa":"Muscarinic M2 receptor","graph1":"Urology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"URO-902","moa":"Maxi-K protein expression","graph1":"Urology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Sumitovant Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Urovant Sciences \/ Sumitovant Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"Urovant Sciences \/ Sumitovant Biopharma"},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tolterodine Tartrate","moa":"Muscarinic M3 receptor","graph1":"Urology","graph2":"Approved","graph3":"Unichem Laboratories Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Unichem Laboratories Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Unichem Laboratories Limited \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"OnabotulinumtoxinA","moa":"","graph1":"Urology","graph2":"Phase II","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intravesical Instillation","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Antares Pharma","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Desmopressin Acetate","moa":"Vasopressin receptor","graph1":"Urology","graph2":"Approved","graph3":"Ferring Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Ferring Pharmaceuticals \/ Antares Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Ferring Pharmaceuticals \/ Antares Pharma"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Urovant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sunovion Pharmaceuticals \/ Urovant Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Sunovion Pharmaceuticals \/ Urovant Sciences"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"","graph1":"Urology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"","sponsorNew":"Lipella Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Sumitovant Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2020","type":"Merger","leadProduct":"Vibegron","moa":"","graph1":"Urology","graph2":"Phase III","graph3":"Urovant Sciences","amount2":0.57999999999999996,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0.57999999999999996,"dosageForm":"","sponsorNew":"Urovant Sciences \/ Sumitovant Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Urovant Sciences \/ Sumitovant Biopharma"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Urovant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"BioSpecifics","sponsor":"Endo Pharm","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"Collagenase Clostridium Histolyticum","moa":"","graph1":"Urology","graph2":"Approved","graph3":"BioSpecifics","amount2":0.54000000000000004,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0.54000000000000004,"dosageForm":"Injection","sponsorNew":"BioSpecifics \/ Endo Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"BioSpecifics \/ Endo Pharmaceuticals"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Oxybutynin Hydrochloride","moa":"Muscarinic M2 receptor","graph1":"Urology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Pharma Science \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Mirabegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"OnabotulinumtoxinA","moa":"SNAP25","graph1":"Urology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Altasciences Company Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Altasciences Company Inc \/ Not Applicable"},{"orgOrder":0,"company":"Kyorin Pharmaceutical","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved","graph3":"Kyorin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kyorin Pharmaceutical \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Kyorin Pharmaceutical \/ Eisai"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Mirabegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Urovant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Trigone Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Oxybutynin","moa":"Muscarinic M1\/M2\/M3 receptor","graph1":"Urology","graph2":"Preclinical","graph3":"Trigone Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Trigone Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Trigone Pharma \/ Not Applicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Imbrium Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"IMB-150","moa":"","graph1":"Urology","graph2":"Preclinical","graph3":"PureTech Health","amount2":0.059999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ Imbrium Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"PureTech Health \/ Imbrium Therapeutics"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Urovant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Versameb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"VMB-100","moa":"","graph1":"Urology","graph2":"Preclinical","graph3":"Versameb","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Versameb \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Versameb \/ Not Applicable"},{"orgOrder":0,"company":"Vaneltix Pharma","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunits","graph1":"Urology","graph2":"Phase II","graph3":"Vaneltix Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0.01,"dosageForm":"Prefilled Syringe","sponsorNew":"Vaneltix Pharma \/ Hyloris","highestDevelopmentStatusID":"8","companyTruncated":"Vaneltix Pharma \/ Hyloris"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fesoterodine","moa":"Muscarinic M2 receptor","graph1":"Urology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Extended-Release Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"Serenity LLC","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Agreement","leadProduct":"Desmopressin Acetate","moa":"Vasopressin receptor","graph1":"Urology","graph2":"Approved","graph3":"Serenity LLC","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0.02,"dosageForm":"","sponsorNew":"Serenity LLC \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Serenity LLC \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Touchlight","sponsor":"Versameb","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"VMB-100","moa":"","graph1":"Urology","graph2":"Preclinical","graph3":"Touchlight","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"","sponsorNew":"Touchlight \/ Versameb","highestDevelopmentStatusID":"4","companyTruncated":"Touchlight \/ Versameb"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fexapotide triflutate","moa":"HDAC10","graph1":"Urology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intraprostatic Injection","sponsorNew":"Nymox Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Hmaxi-K","moa":"","graph1":"Urology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intradetrusor Injection","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Serenity Pharmaceuticals","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Desmopressin Acetate","moa":"Vasopressin receptor","graph1":"Urology","graph2":"Approved","graph3":"Serenity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Serenity Pharmaceuticals \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Serenity Pharmaceuticals \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Urovant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Vensica Therapeutics","sponsor":"Merz Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"IncobotulinumtoxinA","moa":"SNAP25","graph1":"Urology","graph2":"Phase III","graph3":"Vensica Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0.02,"dosageForm":"Intramuscular Injection","sponsorNew":"Vensica Therapeutics \/ Merz Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Vensica Therapeutics \/ Merz Therapeutics"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"hMaxi-K","moa":"","graph1":"Urology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intradetrusor Injection","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Urovant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Hmaxi-K","moa":"","graph1":"Urology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Urovant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"SNAP25","graph1":"Urology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved","graph3":"Urovant Sciences","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Pierre Fabre","highestDevelopmentStatusID":"12","companyTruncated":"Urovant Sciences \/ Pierre Fabre"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fesoterodine","moa":"Muscarinic M2 receptor","graph1":"Urology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Graminex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Graminex G63 Flower Pollen Extract","moa":"","graph1":"Urology","graph2":"Undisclosed","graph3":"Graminex","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Graminex \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Graminex \/ Not Applicable"},{"orgOrder":0,"company":"Muvon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Autologous Muscle Precursor Cell Therapy","moa":"","graph1":"Urology","graph2":"Phase I","graph3":"Muvon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Muvon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Muvon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Urovant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fexapotide triflutate","moa":"","graph1":"Urology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nymox Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"IMB-150","moa":"","graph1":"Urology","graph2":"Phase I","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"","sponsorNew":"Imbrium Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Imbrium Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Finasteride","moa":"","graph1":"Urology","graph2":"Approved","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Prague Scientific \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Prague Scientific \/ Not Applicable"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fexapotide triflutate","moa":"","graph1":"Urology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nymox Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Kyorin Pharmaceutical","sponsor":"Sumitomo","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Vibegron","moa":"","graph1":"Urology","graph2":"Approved","graph3":"Kyorin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kyorin Pharmaceutical \/ Sumitomo","highestDevelopmentStatusID":"12","companyTruncated":"Kyorin Pharmaceutical \/ Sumitomo"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Solifenacin Succinate","moa":"","graph1":"Urology","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo Pharma Limited \/ Not Applicable"},{"orgOrder":0,"company":"Cook MyoSite","sponsor":"Lipella Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Tacrolimus","moa":"","graph1":"Urology","graph2":"Phase II","graph3":"Cook MyoSite","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Cook MyoSite \/ Lipella Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Cook MyoSite \/ Lipella Pharmaceuticals"},{"orgOrder":0,"company":"Veru","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Finasteride","moa":"","graph1":"Urology","graph2":"Approved","graph3":"Veru","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Veru \/ Blue Water Vaccines","highestDevelopmentStatusID":"12","companyTruncated":"Veru \/ Blue Water Vaccines"},{"orgOrder":0,"company":"Valensa International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Serenoa Repens Extract","moa":"","graph1":"Urology","graph2":"Preclinical","graph3":"Valensa International","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"","sponsorNew":"Valensa International \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Valensa International \/ Not Applicable"},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"IQVIA","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Finasteride","moa":"","graph1":"Urology","graph2":"Approved","graph3":"Blue Water Vaccines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Blue Water Vaccines \/ IQVIA","highestDevelopmentStatusID":"12","companyTruncated":"Blue Water Vaccines \/ IQVIA"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Vaneltix Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Lidocaine","moa":"","graph1":"Urology","graph2":"Phase II","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Hyloris Pharmaceuticals \/ Vaneltix Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Hyloris Pharmaceuticals \/ Vaneltix Pharma"},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Finasteride","moa":"","graph1":"Urology","graph2":"Approved","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Veru \/ Not Applicable"},{"orgOrder":0,"company":"EG 427","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Series A Financing","leadProduct":"EG110A","moa":"","graph1":"Urology","graph2":"IND Enabling","graph3":"EG 427","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Urology","amount2New":0.02,"dosageForm":"","sponsorNew":"EG 427 \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"EG 427 \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Solifenacin Succinate","moa":"","graph1":"Urology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tamsulosin","moa":"","graph1":"Urology","graph2":"Approved","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cipla \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ Not Applicable"},{"orgOrder":0,"company":"MSN Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Solifenacin Succinate","moa":"","graph1":"Urology","graph2":"Approved","graph3":"MSN Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"MSN Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MSN Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Camber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Solifenacin Succinate","moa":"","graph1":"Urology","graph2":"Approved","graph3":"Camber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Camber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Camber Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Adalvo","sponsor":"Adamed Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Solifenacin Succinate","moa":"","graph1":"Urology","graph2":"Approved","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Modified Release Tablet","sponsorNew":"Adalvo \/ Adamed Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Adalvo \/ Adamed Pharma"},{"orgOrder":0,"company":"Sawai Pharmaceutical Co., Ltd.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Solifenacin Succinate","moa":"","graph1":"Urology","graph2":"Approved","graph3":"Sawai Pharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sawai Pharmaceutical Co., Ltd. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sawai Pharmaceutical Co., Ltd. \/ Not Applicable"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Vibegron","moa":"","graph1":"Urology","graph2":"Phase III","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sumitomo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo \/ Not Applicable"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Fexapotide triflutate","moa":"","graph1":"Urology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nymox Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Glycologix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"GLX-100","moa":"","graph1":"Urology","graph2":"Phase I","graph3":"Glycologix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"","sponsorNew":"Glycologix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Glycologix \/ Not Applicable"},{"orgOrder":0,"company":"Onconetix","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Finasteride","moa":"","graph1":"Urology","graph2":"Approved","graph3":"Onconetix","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Onconetix \/ Blue Water Vaccines","highestDevelopmentStatusID":"12","companyTruncated":"Onconetix \/ Blue Water Vaccines"},{"orgOrder":0,"company":"EG 427","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"EG110A","moa":"","graph1":"Urology","graph2":"IND Enabling","graph3":"EG 427","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"","sponsorNew":"EG 427 \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"EG 427 \/ Not Applicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Silodosin","moa":"","graph1":"Urology","graph2":"Approved","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Not Applicable"},{"orgOrder":0,"company":"Dongkook Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dutasteride","moa":"","graph1":"Urology","graph2":"Phase III","graph3":"Dongkook Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dongkook Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dongkook Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Versameb","sponsor":"Touchlight","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"VMB-100","moa":"","graph1":"Urology","graph2":"Preclinical","graph3":"Versameb","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"","sponsorNew":"Versameb \/ Touchlight","highestDevelopmentStatusID":"4","companyTruncated":"Versameb \/ Touchlight"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Mirabegron","moa":"","graph1":"Urology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Vibegron","moa":"","graph1":"Urology","graph2":"Approved","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pierre Fabre \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pierre Fabre \/ Not Applicable"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Vibegron","moa":"","graph1":"Urology","graph2":"Phase III","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sumitomo Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Vibegron","moa":"","graph1":"Urology","graph2":"Approved","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"","sponsorNew":"Pierre Fabre \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pierre Fabre \/ Not Applicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Trospium Chloride","moa":"","graph1":"Urology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target